Skip to main content
. 2021 Feb 16;55(4):646–655. doi: 10.1007/s43441-021-00263-2

Table 1.

Participants’ characteristics.

Stakeholder group n (%), N = 145
Pharmaceutical company and large med-tech 31 (21)
Academic 26 (18)
Regulator 17 (12)
Healthcare professional 14 (10)
Patient representative 14 (9)
Small- or medium-size enterprise 9 (6)
Health Technology Assessment agency 5 (3)
Ethicists 3 (2)
Trade association 2 (1)
Other* 26 (18)
Years of experience in regulatory science n (%)
Less than 1 year of experience 9 (6)
2 – 5 years 37 (25)
6 – 10 years 18 (12)
More than 10 years 81 (56)

*Other: regulatory consultancy, government body, clinical research organisation/practitioner, service provider to the pharma industry.